Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.Community Guidelines: http://bit.ly/ArvinasCG

ArrowMark Partners

Avidity Partners

BB Biotech Ventures

Great Point Partners

Surveyor Capital

RTW Investments

Boxer Capital

Citadel Global Equities

EcoR1 Capital

RA Capital Management

5AM Ventures

Hillhouse Capital Group

Sirona Capital

Canaan Partners

Deerfield

New Leaf Venture Partners

Nextech Invest

OrbiMed

Arvinas

Pin Therapeutics is a competitor of Arvinas in the biopharmaceutical industry, focusing on developing therapies for debilitating and life-threatening diseases.

Pin Therapeutics

FIMECS is another competitor of Arvinas in the biopharmaceutical industry, dedicated to developing therapies for degrading disease-causing proteins.

FIMECS

Arvinas, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins using its proprietary PROTAC® protein degradation platform.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 2:56 PM	beaa9827
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 2:56 PM	0b0c0220
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	059964dd
crunchbase profile	general	Nov 27, 2024 2:28 PM	10161ac0
li profile	general	Mar 4, 2024 2:56 PM	2025a665
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 2:56 PM	d45c274f
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARVINAS

Arvinas, Inc.

Last Close

25.11

22/11 21:00

Market Cap

1.80B

Beta: -

Volume Today

1.04M

Avg: -